Literature DB >> 11244285

Frontotemporal lobar degeneration. An update on clinical, pathological and genetic findings.

M Tolnay1, A Probst.   

Abstract

Frontotemporal lobar degeneration is the second most common form of cortical dementia in the presenium after Alzheimer's disease. Clinically, based on consensus guidelines, three distinct disease entities can be distinguished: frontotemporal dementia, semantic dementia and progressive nonfluent aphasia. Dementia of frontal type and motor neuron disease inclusion dementia are the most frequent neuropathological subtypes of frontotemporal lobar degeneration. By using immunohistochemistry, the latter is characterized by the presence of filamentous ubiquitin-reactive but tau-negative inclusions in nerve cell bodies and neurites. In contrast, Pick's disease and familial frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) are both characterized by abundant filamentous nerve cell inclusions made up of the microtubule-associated protein tau. The recent discovery of more than 15 different mutations in the tau gene in FTDP-17 brought the tau protein to the centre stage. These findings had a major impact on our understanding of neurodegenerative disorders characterized by tau filamentous inclusions in neurones and/or glial cells which are grouped under the generic term of tauopathies. However, as exciting these new molecular insights are, it would be inappropriate to lump frontotemporal lobar degeneration as tauopathies. Recent neuropathological and genetic data strongly suggest that there is more than one genetic background for frontotemporal lobar degeneration. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244285     DOI: 10.1159/000052763

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  4 in total

1.  Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.

Authors:  Deepak M Sampathu; Manuela Neumann; Linda K Kwong; Thomas T Chou; Matthew Micsenyi; Adam Truax; Jennifer Bruce; Murray Grossman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

Review 2.  Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.

Authors:  D Schenk; D Games; P Seubert
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

3.  History, present, and progress of frontotemporal dementia in china: a systematic review.

Authors:  Ru-Jing Ren; Yue Huang; Gang Xu; Chun-Bo Li; Qi Cheng; Sheng-Di Chen; Gang Wang
Journal:  Int J Alzheimers Dis       Date:  2012-03-25

Review 4.  Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.

Authors:  Elise Liu; Léa Karpf; Delphine Bohl
Journal:  Front Mol Neurosci       Date:  2021-12-14       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.